探讨转化生长因子β1（TGF-β1）对胰腺癌细胞系肿瘤干细胞标记物CD133表达的影响。

将三种胰腺癌细胞系（AsPc-1、Panc-1和SW1990）分别分成对照组及实验组，三种细胞系中对照组予以10 μl CD133抗体及90 μl磷酸盐缓冲液（PBS）标记液，实验组予以10 μg/L TGF-β1及90 μl PBS标记液。运用流式细胞计数（FACS）评估TGF-β1对Panc-1、AsPc-1和SW1990中CD133表达的影响；同时，采用磁性活化细胞分选技术（MACS）筛选出三种细胞系CD133阴性细胞，分成Blank组、T组及T + I组，T + I组同时加入10 μg/L浓度的TGF-β1以及10 μmol /L TGF-β1抑制剂，Blank组仅添加等量的PBS溶液，T组中加入10 μg/LTGF-β1及与抑制剂等量的PBS溶液。采用FACS评估TGF-β1及其特异性抑制剂对胰腺癌CD133阴性细胞的影响。

AsPc-1[（1.63 ± 0.21）% vs.（0.63 ± 0.12）%，t = 7.276，P = 0.002]、Panc-1[（3.48 ± 1.26）% vs.（0.66 ± 0.22）%，t = 4.924，P = 0.001]和SW1990[（3.83 ± 0.71）% vs.（0.90 ± 0.44）%，t = 6.102，P = 0.004]细胞系中实验组CD133阳性率显著高于对照组。同时，由MACS分选后的CD133阴性细胞中，AsPc-1[（1.70 ± 0.66）%、（0.50 ± 0.00）%、（0.64 ± 0.21）%]、Panc-1[（1.45 ± 0.53）%、（0.50 ± 0.00）%、（0.42 ± 0.17）%]和SW1990[（1.68 ± 1.26）%、（0.50 ± 0.00）%、（0.62 ± 0.11）%]中T组CD133阳性率均显著高于Blank组及T + I组（P均< 0.05）。

TGF-β1可以使胰腺癌细胞获得肿瘤干细胞能力，并且该现象可以被TGF-β1抑制剂所阻断。

To investigate the effect of CD133 on pancreatic carcinoma induced by transforming growth factor beta1 (TGF-β1).

The pancreatic cancer cells were randomly divided into the control group and experimental group in AsPc-1, Panc-1 and SW1990, respectively. The control group received 10 μl CD133 antibody and 90 μl phosphate buffered saline (PBS), and the experimental group were given 10 μg/L TGF-β1 and 90 μl PBS. Fluorescence-activated cell sorting (FACS) was used to evaluate CD133 positive rate. The magnetic activated cell sorting (MACS) was used to sort CD133 negative cells, then CD133 negative cells were randomly divided into the Blank group, T group and T + I group in the AsPc-1, Panc-1 and SW1990, respectively. The T + I group were given 10 μg/L TGF-β1 and 10 μmol/L TGF-β1 inhibitors, Blank group only received the same amount of PBS, and the T group received 10 μg/L TGF-β1 and the same amount of TGF-β1 inhibitors. CD133 positive rate was evaluated by FACS again after the treatment of TGF-β1 and its inhibitor.

CD133 positive rates of AsPc-1 [(1.63 ± 0.21)% vs. (0.63 ± 0.12)%, t = 7.276, P = 0.002], Panc-1 [(3.48 ± 1.26)% vs. (0.66 ± 0.22)%, t = 4.924, P = 0.001] and SW1990 [(3.83 ± 0.71)% vs. (0.90 ± 0.44)%, t = 6.102, P = 0.004] in the experimental group were much higher than those in the control group. Moreover, CD133 negative cells sorted by MACS were also changed to positive, and the CD133 positive rates of AsPc-1[(1.70 ± 0.66)%, (0.50 ± 0.00)%, (0.64 ± 0.21)%], Panc-1[(1.45 ± 0.53)%, (0.50 ± 0.00)%, (0.42 ± 0.17)%] and SW1990 [(1.68 ± 1.26)%, (0.50 ± 0.00)%, (0.62 ± 0.11)%] in the T group increased dramatically as compared with those in the Blank group and T + I group (all P< 0.05).

TGF-β1 can enable pancreatic cancer cells to acquire cancer stem cell's features and this phenomenon can be suppressed by the inhibitors.